| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer
1 Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
2 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
3 Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York
4 Mallinckrodt Institute, Washington University School of Medicine, St. Louis, Missouri
This trial was an initial assessment of the feasibility, in vivo targeting, and biokinetics of 16ß-18F-fluoro-5
-dihydrotestosterone (18F-FDHT) PET in patients with metastatic prostate cancer to assess androgen receptor expression. Methods: Seven patients with progressive clinically metastatic prostate cancer underwent 18F-FDG and 18F-FDHT PET scans in addition to conventional imaging methods. Three patients had their studies repeated 1 mo later, 2 while on testosterone therapy, and the third after treatment with 17-allylamino-17-demethoxygeldanamycin (17-AAG). High-pressure liquid radiochromatography was used to separate 18F-FDHT from radiolabeled metabolites. Lesion-by-lesion comparisons between the 18F-FDHT, 18F-FDG, and conventional imaging methods were performed. Results: Metabolism of 18F-FDHT was rapid, with 80% conversion within 10 min to radiolabeled metabolites that circulated bound to plasma proteins. Tumor uptake was rapid and tumor retention was prolonged. Fifty-nine lesions were identified by conventional imaging methods. 18F-FDG PET was positive in 57 of 59 lesions (97%), with an average lesion maximum standardized uptake value (SUVmax) = 5.22. 18F-FDHT PET was positive in 46 of 59 lesions (78%), with the average positive lesion SUVmax = 5.28. Treatment with testosterone resulted in diminished 18F-FDHT uptake at the tumor site. Conclusion: 18F-FDHT localizes to tumor sites in patients with progressive clinically metastatic prostate cancer and may be a promising agent to analyze antigen receptors and their impact on the clinical management of prostate cancer.
Key Words: 16ß-18F-fluoro-5-dihydrotestosterone • PET • prostate cancer • androgen receptor
This article has been cited by other articles:
|
|
 |
|
  E. E. Parent, C. S. Dence, T. L. Sharp, M. J. Welch, and J. A. Katzenellenbogen 7{alpha}-18F-Fluoromethyl-Dihydrotestosterone and 7{alpha}-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone-Binding Globulin for Steroidal Radiopharmaceuticals J. Nucl. Med., June 1, 2008; 49(6): 987 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Mease, C. L. Dusich, C. A. Foss, H. T. Ravert, R. F. Dannals, J. Seidel, A. Prideaux, J. J. Fox, G. Sgouros, A. P. Kozikowski, et al. N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-L-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3036 - 3043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Schuster, J. R. Votaw, P. T. Nieh, W. Yu, J. A. Nye, V. Master, F. D. Bowman, M. M. Issa, and M. M. Goodman Initial Experience with the Radiotracer Anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid with PET/CT in Prostate Carcinoma J. Nucl. Med., January 1, 2007; 48(1): 56 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher and C. L. Sawyers Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Foss, R. C. Mease, H. Fan, Y. Wang, H. T. Ravert, R. F. Dannals, R. T. Olszewski, W. D. Heston, A. P. Kozikowski, and M. G. Pomper Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4022 - 4028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Zanzonico, R. Finn, K. S. Pentlow, Y. Erdi, B. Beattie, T. Akhurst, O. Squire, M. Morris, H. Scher, T. McCarthy, et al. PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer J. Nucl. Med., November 1, 2004; 45(11): 1966 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Scheffel and M. G. Pomper PET Imaging of GRP Receptor Expression in Prostate Cancer J. Nucl. Med., August 1, 2004; 45(8): 1277 - 1278. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
